Brief: Actinium Pharmaceuticals Successfully Completes First Dosing Cohort In The Phase 1 Study Of Actimab-A And Venetoclax Combination Therapy In Relapsed/Refractory Aml Patients
23/09/2020 12:27
Sept 23 (Reuters) - Actinium Pharmaceuticals Inc ATNM.A :
* ACTINIUM PHARMACEUTICALS SUCCESSFULLY COMPLETES FIRST
DOSING
COHORT IN THE PHASE 1 STUDY OF ACTIMAB-A AND VENETOCLAX
COMBINATION THERAPY IN RELAPSED/REFRACTORY AML PATIENTS
* ACTINIUM PHARMACEUTICALS INC - ACTINIUM PLANS TO REPORT
STUDY
PROOF OF CONCEPT RESULTS IN 2021.
Source text for Eikon: ID:nPn7LTFMya
Further company coverage: ATNM.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Actinium Pharmaceuticals
See all newsBrief: Actinium Pharmaceuticals - Receives Two Canadian Patent Allowances For Actimab-A And Iomab-Act Programs
Brief: ctinium’s Atnm-400 Shows Strong Efficacy in TNBC, Beats Therapy Resistance at SABCS
Brief: Actinium Pharmaceuticals Says ATNM-400 Shows Superior Efficacy To Xtandi In Prostate Cancer
Brief: Actinium Pharmaceuticals Announces ATNM-400 A Novel Non-PSMA Targeting First In Class Prostate Cancer Radiotherapy Leveraging Actinium-225
Brief: Actinium Pharmaceuticals Announces Supply Agreement With Eckert & Ziegler For AC-225 Radioisotope To Support Comprehensive Development Activities